Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Russell 2000 ETF (NY:IWM)

216.17 +0.69 (+0.32%)
Streaming Delayed Price Updated: 10:13 AM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 ETF

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
Financial Markets Report For Wednesday, March 5
In this video, Ira Epstein reviews the activity in the Financial Markets after the day that just ended, Wednesday, March 5. 
Via Talk Markets
Topics Commodities Cryptocurrencies Currencies/Forex
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates
Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years. 
Via Stocktwits
Nasdaq, S&P 500 Bounce Back As Trump’s Tariff Pause Calms Markets
Via Talk Markets
Topics Government Stocks Stocks / Equities
Upcoming "Death Cross" For Russell 2000
There was some modest buying today from the open, but volume was light and markets are below trading range support established during the latter part of 2024. 
Via Talk Markets
Topics Stocks / Equities
Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday?
The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points.  
Via Benzinga
Topics Government Stocks
Trump Bump Turns Into A Slump: SPY Sinks As S&P 500 Erases Post-Election Gains
Small caps, once darlings of the so-called "Trump trade," are crumbling. The Russell 2000 soared 5.84% after Election Day. Now it's down 8%. 
Via Benzinga
Topics Government Stocks
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy. 
Via Stocktwits
Financial Markets Report For Tuesday, March 4
In this video, Ira Epstein reviews the activity in the Financial Markets after the day that just ended, Tuesday, March 4. 
Via Talk Markets
Topics Commodities Cryptocurrencies Currencies/Forex
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key... 
Via Stocktwits
This ETF Saw Huge Inflows And Topped The Vanguard S&P 500 ETF In Assets
Which ETFs saw the most outflows last month? 
Via Talk Markets
Topics ETFs Stocks
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions. 
Via Benzinga
Topics World Trade
Paysafe Stock Tumbles Pre-Market After Disappointing Q4 Earnings, 2025 Guidance: Retail Stays Bearish
Paysafe said its Q4 results were significantly impacted by accelerated merchant exits and associated credit losses during the quarter. 
Via Stocktwits
Aurora Innovation Analyst Predicts 73% Upside For Stock, Eyeing April Rollout Of Commercial Driverless Operation: Retail Convinced Of Strong 2025
Morgan Stanley analyst Ravi Shanker said Aurora is leading the charge with the “most sophisticated on-highway Class 8 autonomous solution among peers.” 
Via Stocktwits
Financial Markets Report For Monday, March 3
In this video, Ira Epstein reviews the activity in the Financial Markets after the day that just ended, Monday, March 3. 
Via Talk Markets
Topics Commodities Cryptocurrencies Currencies/Forex
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026. 
Via Stocktwits
The S&P Gave Up All Of Friday's Gains
Sellers whipped bulls with an undercut of Friday's lows on higher volume disribution. There was no denying which side of the market traders were sitting at. 
Via Talk Markets
Topics Stocks Stocks / Equities
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
Amidst Elevated Valuations, Macro/Policy Uncertainty, Relief Rally Possible In Equities
The S&P 500 trades at elevated multiples. Earnings expectations for this year and next are very high. Enter macro uncertainty surrounding the fiscal/tariff policy of the Trump administration. 
Via Talk Markets
Topics Bonds Government Stocks
Retail Traders Divided On March Market Moves After February Dip — Most Want To Sit Out Or Go For Buffett-Style Cash Play
The potential impact from President Donald Trump’s tariffs, the continuing uncertainty surrounding the Federal Reserve rate outlook and mixed earnings served as pushbacks in February. 
Via Stocktwits
Topics Economy Government World Trade
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 
Via Stocktwits
Nasdaq Tests 200-Day MA As Russell 2000 Breaks Weekly Trend Support
The Russell 2000 broke below support of the rising channel on the weekly time frame. Meanwhile, the Nasdaq finished the week with a bullish piercing pattern following a successful test of the 200-day... 
Via Talk Markets
Topics ETFs Stocks / Equities
Semiconductors Fail A Key Support Level - And More
It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average. 
Via Talk Markets
Topics ETFs
Peek Into The Future Thru Futures, Hedge Fund Positions - March 2
Since September last year, 23 – or thereabouts – has posed difficulty for volatility bulls, and this trend prevailed this week as well. VIX for now is probably headed lower. 
Via Talk Markets
Topics Bonds Currencies/Forex Stocks
Powerful UnR Session As All Four Market Indices Lockstep Rally Into The Close; Bear Trap Set?
In this video lesson, I review the overall market, the recent bearish sentiment, and one new swing trade idea for Monday's session. 
Via Talk Markets
Topics Stocks / Equities
Market Meltdown Or Bounce Back? Here’s What Traders Need To Know
As February draws to a close, markets remain volatile amid shifting macroeconomic conditions, geopolitical tensions, and sector-specific developments. 
Via Talk Markets
Topics Stocks / Equities
Buckle Up, This Bull Market Might Be Ending
The markets are setting up for a big test. 
Via Talk Markets
Topics ETFs Stocks / Equities
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA) 
Via Benzinga
IWM ETF: Russell 2000 Crashes As Fear And Greed Index Tumbles
The Russell 2000 index crashed for the second consecutive week as the fear and greed index moved to the extreme fear level. 
Via Talk Markets
Topics ETFs
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder. 
Via Stocktwits
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.